• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Former i3 CEO Bilawsky tapped to lead Precision Health Economics

Former i3 CEO Bilawsky tapped to lead Precision Health Economics

October 19, 2012
CenterWatch Staff

Health economics partnership Precision Health Economics (PHE) has named Glenn Bilawsky as its CEO. The healthcare consultancy, known for its exceptional, highly decorated and connected team has experienced rapid growth and is looking to Bilawsky to underpin its success with a strategy and business platform that will ensure stability while accelerating expansion of the business.

Bilawsky served as CEO of the i3 division of UnitedHealth Group for more than eight years. He brings more than a quarter century of pharmaceutical and contract research experience and has been instrumental in helping several organizations achieve global leadership positions.

"We have a slate of brilliant researchers and analysts who are in demand by our clients throughout the healthcare industry and in the highest levels of government,” said Darius Lakdawalla, co-founder of PHE. “We need a proven leader with the business acumen to refine our strategy while creating and managing a platform for growth.  Glenn is that person."

PHE was formed in 2005 by Tomas Philipson, Dana Goldman and Lakdawalla, all renowned health economists from elite universities. Their goal was to use sophisticated, data-driven analysis tailored to each client's strategic needs, and to improve public policy through insightful, issue-driven research. Today the firm has three offices across the country and a network of affiliated academic economists and clinicians from the world's leading universities. Bilawsky plans to expand the national footprint, then move into Europe and Asia.

"This is a rare opportunity to step in at this stage to help shape PHE's growth and provide the strategic and operational platform to fuel its expansion," said Bilawsky. "The cost of healthcare is a global concern. There is a rapidly growing need for information and guidance from a trusted source for all constituents: payers; providers; and manufacturers of pharma, biotechnology, medical device and diagnostic products. I have the good fortune to build on PHE's many assets, which include its preeminent expertise and brand reputation in both the total healthcare and government markets. The PHE team and its network have no peer in the industry."

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing